Olmesartan Medoxomil Accord (Olmesartan Medoxomil)

Olmesartan Medoxomil selectively blocks the angiotensin II type 1 (AT1) receptors on vascular smooth muscle and adrenal glands. This prevents angiotensin II‑induced vasoconstriction and aldosterone release, leading to vasodilation, reduced sodium retention, and ultimately lower arterial pressure.

The appropriate dose of Olmesartan Medoxomil Accord is determined by the prescribing clinician based on the patient’s blood pressure, renal function, and overall health status. Dosage adjustments are made individually; patients should follow the prescriber’s instructions precisely.

Olmesartan Medoxomil is classified as Pregnancy Category D, indicating evidence of fetal risk. It is not recommended for use during pregnancy. Limited data are available for breastfeeding; therefore, the drug should be avoided unless the potential benefit outweighs the risk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After verification of trade or institutional credentials, the sales team will provide pricing, availability, shipping details, and any required import documentation.

Olmesartan, an ARB, offers blood‑pressure control comparable to ACE inhibitors but with a lower incidence of cough and angio‑edema. Unlike calcium‑channel blockers, it directly blocks the renin‑angiotensin system, making it useful for patients who need renin‑angiotensin inhibition without the side‑effects associated with ACE inhibitors.

Store the tablets at room temperature, preferably below 25 °C. Keep them in the original blister pack or container, protect from moisture, heat, and direct sunlight. Do not refrigerate or freeze the product.

Olmesartan Medoxomil Accord is taken orally, usually once daily, with or without food. Swallow the tablet whole with a glass of water. Patients should not crush or chew the tablet unless specifically instructed by a healthcare professional.

Serious adverse reactions include angio‑edema, severe hypotension, acute renal failure, and hyperkalemia. Patients should seek immediate medical attention if they experience swelling of the face or throat, a sudden drop in blood pressure, marked weakness, or signs of elevated potassium such as irregular heartbeat.

Olmesartan Medoxomil Accord is contraindicated in patients with known hypersensitivity to the drug or any ARB, in pregnant women, and in individuals with severe hepatic impairment. Caution is advised for patients with bilateral renal artery stenosis, severe renal dysfunction, or those taking potassium‑sparing diuretics without monitoring.